晚期NSCLC患者ERCC1、RRM1表达对GP方案化疗疗效预测的相关性研究(3)
 |
| 第1页 |
参见附件。
[11] Navneet Singh，Amanjit Bal，Ashutosh N Aggarwal， et al. Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers[J]. Future Oncology，2010，6(5)：741–767.
[12] Craig Reynold，Coleman Obasaju， Michael J. Schell，et al. Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer[J]. Clinical Oncology， 2009，27(34)：5808-5815.
[13] Rafael Rosell， Kathleen D. Danenberg， Vincente Alberola，et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients[J]. clinical Cancer Research，2004，10，1318-1325.
[14] Rafael Rosell， Enriqueta Felip，Miquel Taron，et al.Gene Expression as a Predictive Marker of Outcome in Stage ⅡB-ⅢA-ⅢB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery[J].clinical Cancer Research，2004，10(12)：4215s-4219s.
(收稿日期：)
您现在查看是摘要介绍页，详见PDF附件。